WHAT IS CLAIMED IS:

1. Use of a purified peptide for the manufacture of a medicament for the treatment of an inflammatory lung disease in a subject in need thereof, wherein the purified peptide comprises an amino acid sequence according to SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.
2. The use of claim 1, wherein the inflammatory lung disease comprises asthma, chronic obstructive pulmonary disease (COPD), or COVID-19.
3. The use of claim 2, wherein asthma is selected from a group consisting of type 2 asthma, non-type 2 asthma, early onset asthma, late onset asthma, obesity associated asthma, exercise induced asthma, asthma exacerbations, asthma associated with pollutants to cigarette smoke, or asthma associated with infections.
4. The use of any one of claims 1-3, wherein the purified peptide is in a preparation for aerosolization, or subcutaneous injection.
5. The use of any one of claims 1-4, wherein the purified peptide is to be administered via nasal inhalation, or subcutaneously.
6. The use of any one of claims 1-5, wherein the purified peptide is to be administered with one or more additional therapeutic agents.
7. The use of claim 6, wherein the one or more therapeutic agents are to be administered concurrently or in series with the purified peptide.
8. The use of claim 6 or claim 7, wherein the one or more therapeutic agents comprise short-acting beta2-adrenoceptor agonists (SABA), long acting beta agonist (LABA), anticholinergic medications, leukotriene receptor antagonists, or a combination thereof.
9. The use of claim 8, wherein the anticholinergic medications comprise ipratropium bromide, inhaled epinephrine and inhaled corticosteroids.
10. The use of claim 9, wherein the inhaled corticosteroids comprise budesonide, fluticasone, mometasone or ciclesonide.
11. A purified peptide comprising an amino acid sequence according to SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.
12. The peptide of claim 11, wherein the purified peptide is in a preparation for aerosolization or subcutaneous injection.
13. The peptide of claim 11 or 12, wherein the purified peptide is administered via nasal inhalation, or subcutaneously.

14. The peptide of claim 11 or 12, wherein the purified peptide is administered with one or more additional therapeutic agents.
15. The peptide of claim 14, wherein the one or more therapeutic agents are administered concurrently or in series with the purified peptide.
16. The peptide of claim 14 or 15, wherein the one or more therapeutic agents comprise short-acting beta2-adrenoceptor agonists (SABA), long acting beta agonist (LABA), anticholinergic medications, leukotriene receptor antagonists, or a combination thereof. \
17. The peptide of claim 16, wherein the anticholinergic medications comprise ipratropium bromide, inhaled corticosteroids or systemic corticosteroids.
18. The peptide of claim 17, wherein the inhaled corticosteroids or systemic corticosteroids comprise budesonide, fluticasone, mometasone or ciclesonide.